Home›Nitisinone›Nitisinone + Sensitive Cyp3a Substrates

Does Nitisinone Interact with Sensitive Cyp3a Substrates?

Nitisinone and Sensitive Cyp3a Substrates have a major drug interaction according to U.S. FDA drug labeling data. Nitisinone is a moderate CYP2C9 inhibitor that may increase exposure of co-administered drugs metabolized by CYP2C9, requiring dosage reduction by half and additional adjustments to maintain therapeutic concentrations. The mechanism involves cyp2c9 inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Nitisinone Class
4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Nitisinone and Sensitive Cyp3a Substrates occurs because cyp2c9 inhibition. Clinically, this means nitisinone is a moderate cyp2c9 inhibitor that may increase exposure of co-administered drugs metabolized by cyp2c9, requiring dosage reduction by half and additional adjustments to maintain therapeutic concentrations. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Nitisinone and your doctor is considering prescribing Sensitive Cyp3a Substrates (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Nitisinone(Orfadin)+💊 Sensitive Cyp3a Substrates(Fluorimax Sensitive)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor
Drug B class
—
Source
NLP:nitisinone

What this means in plain English

Nitisinone is a moderate CYP2C9 inhibitor that may increase exposure of co-administered drugs metabolized by CYP2C9, requiring dosage reduction by half and additional adjustments to maintain therapeutic concentrations.

About Nitisinone and Sensitive Cyp3a Substrates

Nitisinone is a 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor. Nitisinone is also sold under the brand name Orfadin. Nitisinone is taken by mouth.

What the FDA label says

"CYP2C9 inhibition"

📖 Source: NLP:nitisinone

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Nitisinone and Sensitive Cyp3a Substrates against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.